What are the indications, dosing, side effects, and monitoring requirements for triamterene?

Triamterene: Clinical Overview

Triamterene is a potassium-sparing diuretic indicated primarily for edema management in heart failure, cirrhosis, nephrotic syndrome, and as add-on therapy for hypertension, with the critical caveat that it must be used with extreme caution when combined with ACE inhibitors or ARBs due to severe hyperkalemia risk.

Indications

Triamterene is FDA-approved for 1:

• Edema associated with:

  • Congestive heart failure
  • Cirrhosis of the liver
  • Nephrotic syndrome
  • Steroid-induced edema
  • Idiopathic edema
  • Secondary hyperaldosteronism

• Hypertension: Used as add-on therapy, particularly when thiazide-induced hypokalemia persists despite ACE inhibitor therapy 2

Key clinical context: Triamterene is minimally effective as monotherapy 3 and should be combined with thiazide or loop diuretics for optimal effect 4, 5.

Dosing

Adults

Starting dose: 100 mg twice daily after meals 1

Pediatric dosing (off-label):

• Initial: 1-2 mg/kg/day
• Maximum: 3-4 mg/kg/day up to 300 mg/day
• Frequency: Twice daily (BID) 6

Maximum daily dose: 300 mg/day 1

Titration strategy:

• When combined with other diuretics, reduce initial doses of both agents
• Discontinue all potassium supplementation when initiating triamterene 1
• Take after meals to minimize GI upset 1
• Morning dosing preferred to avoid nocturia 1

Renal Dosing Adjustments

Critical warning: Avoid in patients with significant chronic kidney disease (GFR <45 mL/min) 3. Triamterene requires dose adjustment in renal impairment 7, though specific consensus dosing recommendations are lacking.

Side Effects

Major Adverse Effects

Hyperkalemia is the most serious concern 2:

• Risk dramatically increased when combined with ACE inhibitors, ARBs, or other potassium-sparing agents
• Particularly dangerous in patients with renal insufficiency 1
• Can be life-threatening (potassium >6 mEq/L requires immediate intervention) 1

Renal complications 8:

• Nephrolithiasis (triamterene stones)
• Interstitial nephritis
• Acute renal failure (especially when combined with NSAIDs)
• Abnormal urinary sediment

Other significant effects:

• Hyponatremia (when combined with chlorpropamide) 1
• Hyperuricemia/gout 4
• Glucose intolerance 1
• Rash 2

Drug Interactions

Contraindicated or high-risk combinations:

• NSAIDs: Can precipitate acute renal failure 1, 8
• ACE inhibitors/ARBs: Severe hyperkalemia risk, especially with renal disease 2, 9, 1
• Potassium supplements or salt substitutes: Additive hyperkalemia 9, 1
• Other potassium-sparing diuretics: Compounded hyperkalemia risk 2

Requires monitoring:

• Lithium: Reduced renal clearance, increased toxicity risk 1
• Antihypertensives: Potentiated effects 1

Monitoring Requirements

Heart Failure Patients

Initial monitoring (per European Heart Journal guidelines) 2:

• Check serum potassium and creatinine every 5-7 days after initiation
• Continue every 5-7 days until values are stable
• Once stable: monitor every 3-6 months

Hypertension Patients

Per ACC/AHA guidelines 3:

• Monitor potassium, renal function, and electrolytes shortly after initiating therapy
• Periodic monitoring thereafter

Critical Thresholds

Stop triamterene if:

• Serum potassium persistently >6 mEq/L 1
• Substantial deterioration in renal function 2
• Serum creatinine >2.5 mg/dL (men) or >2.0 mg/dL (women) 10

Normal reference ranges:

• Serum potassium: 3.5-5.0 mEq/L (adults); 7.7 mEq/L (neonates) 1

Clinical Pearls and Pitfalls

When to Use Triamterene

Appropriate scenarios:

1. Persistent hypokalemia despite ACE inhibitor + thiazide therapy 2
2. Severe heart failure despite ACE inhibitor + low-dose spironolactone 2
3. Resistance to loop diuretics in heart failure 6

Blood pressure benefit: Triamterene provides independent BP-lowering effect beyond potassium-sparing action, reducing systolic BP by 1-4 mmHg when added to hydrochlorothiazide 5.

Critical Warnings

Avoid potassium-sparing diuretics during ACE inhibitor initiation 2. This is a Class I recommendation from European guidelines.

Pregnancy: Not routinely recommended; diuretics do not prevent toxemia and expose mother/fetus to unnecessary risk 1. Use only if edema is from pathologic causes, not physiologic pregnancy-related edema.

Renal stone history: Use with extreme caution; triamterene is a component of renal calculi 1.

Gradual withdrawal: In patients on prolonged therapy, withdraw gradually to avoid rebound kaliuresis 1.

Bioavailability Considerations

The combination tablet formulation (Maxzide: 75 mg triamterene/50 mg HCTZ) has superior bioavailability compared to the capsule formulation (Dyazide: 50 mg/25 mg), delivering approximately twice the hydrochlorothiazide to the bloodstream 11.